Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

y Rat Neurons by a GABA-Independent Pathway in presentation P-192. About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the United States Food and Drug Administration, European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our Web Site at: www.neurochem.com.

This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that ac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... a peer-reviewed publication of the results of the ... (RegeneRx,s preservative-free eye drops) for the treatment of ... environment (CAE ® ) model.  The exploratory study ... which were previously disseminated by the Company in ...
(Date:5/22/2015)... 2015 Research and Markets ( ... "Latest Regulations on Pharmaceutical International Multi-Center Clinical ... This is first time in history, ... international multi-center clinical trials of drugs in ... be implemented on March 1, 2015. The guidance ...
(Date:5/22/2015)... , May 22, 2015  China Nepstar Chain ... a leading retail drugstore chain in China ... stores, today announced the resignation of Mr. Fuxiang ... personal reasons, effective immediately. Ms. Rebecca Yingnan Zhang ... the Company,s board of directors, effective immediately. Meanwhile, Ms. ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3
... Mass., Aug. 1, 2011 Merrimack Pharmaceuticals, Inc. ... Administration (FDA) has granted MM-398 orphan drug status ... a novel, stable nanotherapeutic encapsulation of the marketed ... Inc. for development and commercialization in Taiwan under ...
... MUMBAI, India, Aug. 1, 2011 Groupe Athena, Inc. (Pink ... recent fiscal year ended June 30, 2011, more than doubling ... also more than doubled for the same period to $2,106,808 ... D. Purohit stated, "Of course we are very pleased with ...
Cached Medicine Technology:FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer 2Groupe Athena, Inc. Profits Soar on Record Revenues 2Groupe Athena, Inc. Profits Soar on Record Revenues 3
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... Beach, CA (PRWEB) May 23, 2015 Dr. ... Beach, California, has just posted a new article ... gauge repair. As Dr Benvenuti explained in the ... wear enlarged plugs in their earlobes. , Known as “gauging,” ... the earlobe hole, which Dr. Benvenuti said will eventually stretch ...
(Date:5/23/2015)... 2015 Manufacturers are now required to produce ... of 8.2. Experts in the field agree that the regulation ... The HSPF score is what miles per gallon is to ... unit. Although the minimum HSPF score has been raised to ... HSPF score north of 12. Indeed, the regulation was welcomed ...
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on the ... legislature but which has not been signed to date by ... 449 with overwhelming bipartisan support on April 10, 2015, ... This bill ensures that fracking is prohibited in Maryland through ... of fracking to our water supplies and the air we ...
(Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
Breaking Medicine News(10 mins):Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2
... from the University of East Anglia,s Climatic Research Unit (CRU) are ... magazine, ,Dark Matter, calls for a debate into science and transparency. ... In his article, ,Information Gap, leading science writer Fred Pearce argues ... the start, a great deal of time and angst on the ...
... Cambridge, Mass. November 30, 2011 From targeted ... the 21st century may prove to be the age ... though, will be miniscule. Experts in chemistry, applied ... week for the BASF Advanced Research Initiative at Harvard ...
... the nastiest smelling creatures on Earth have skin that ... hold promise for becoming new weapons in the battle ... amphibians so smelly (like rotten fish, for instance) that ... Journal of Proteome Research . Yun Zhang, Wen-Hui ...
... 30 (HealthDay News) -- There may be a link between ... cancer in older women, a new study finds. Researchers ... in the U.S. Women,s Health Initiative study. The women,s fasting ... start of the study and then several more times over ...
... financial interest in imaging equipment are more likely to ... to a study presented today at the annual meeting ... "Self-referral," whereby a non-radiologist physician orders imaging exams ... physician has a financial interest, is a concerning trend ...
... Reporter , TUESDAY, Nov. 29 (HealthDay News) -- Dieters may ... study of 123 overweight or obese women, those who snacked ... skipped a mid-morning nosh. The finding may not relate ... between breakfast and lunch for these snackers, explained study author ...
Cached Medicine News:Health News:Is transparency bad for science? 2Health News:Nano meets pharma at Harvard-BASF symposium 2Health News:Nano meets pharma at Harvard-BASF symposium 3Health News:Women's High Blood Sugar Linked to Colorectal Cancer: Study 2Health News:Self-referral leads to more negative exams for patients 2Health News:Mid-Morning Snacks May Thwart Diets 2Health News:Mid-Morning Snacks May Thwart Diets 3
... The Stellate Harmonie workstation is a ... processing loads, high quality video capability, and ... recording and review functions A framework that ... and archiving of data A centralized database ...
... the capability to acquire images in near-real ... Brightness and Contrast levels, Auto-windowing, Image Manipulation, ... Rhodium spectrum which is best adapted to ... Revolution flat panel digital detector, which is ...
... The P3000 heralds a new concept in ... binocular infrared optical system developed for the P2000. ... standard in which we have paid particular attention ... Our new system is extremely flexible, allowing ...
... Foramen ovale electrodes typically are ... and are positioned on the ... lobe. The ultra-thin 1.0 mm ... firm enough to allow guidance ...
Medicine Products: